Talk:Cabergoline: Difference between revisions
>Dextromethorphan wording |
>Blackhole added summary sheet and substance box, removed picture |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
{{headerpanel|{{Stub}}}} | {{headerpanel|{{Stub}}}} | ||
{{SummarySheet}} | |||
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], | {{SubstanceBox/Cabergoline}} | ||
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease. | |||
Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist. | Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist. | ||
Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, | Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>{{cite journal | vauthors=((Krüger, T. H. C.)), ((Haake, P.)), ((Haverkamp, J.)), ((Krämer, M.)), ((Exton, M. S.)), ((Saller, B.)), ((Leygraf, N.)), ((Hartmann, U.)), ((Schedlowski, M.)) | journal=The Journal of Endocrinology | title=Effects of acute prolactin manipulation on sexual drive and function in males | volume=179 | issue=3 | pages=357–365 | date= December 2003 | issn=0022-0795 | doi=10.1677/joe.0.1790357}}</ref><ref>{{cite journal | vauthors=((Hollander, A. B.)), ((Pastuszak, A. W.)), ((Hsieh, T.-C.)), ((Johnson, W. G.)), ((Scovell, J. M.)), ((Mai, C. K.)), ((Lipshultz, L. I.)) | journal=Sexual Medicine | title=Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | volume=4 | issue=1 | pages=e28-33 | date= March 2016 | issn=2050-1161 | doi=10.1016/j.esxm.2015.09.001}}</ref> | ||
==See also== | ==See also== |